1. AVI: the little biotech that could
- Author
-
Barry, Andrew
- Subjects
AVI BioPharma Inc. -- Product development ,AVI BioPharma Inc. -- Securities ,Pharmaceutical industry -- Product development ,Pharmaceutical industry -- Securities ,Duchenne muscular dystrophy -- Drug therapy ,Stocks -- Prices and rates ,Stocks -- Evaluation ,Company securities ,Banking, finance and accounting industries ,Business - Abstract
AVI Biopharma announced encouraging results for its Duchenne muscular dystrophy drug which could be the first effective treatment against this disease which affects around 10,000 people in the U.S. alone. Its stock, which at $1.40 is near its year-ago levels, could rise if AVI gets a deep-pocketed drug partner.
- Published
- 2010